Clinical Trials Logo

Skin Graft Scar clinical trials

View clinical trials related to Skin Graft Scar.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06044519 Completed - Clinical trials for Donor Site Complication

A Single Center Trial of Donor Site Wound Dressings After Split Thickness Skin Grafting.

Start date: August 1, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial] is to compare different types of dressings used and there outcomes on STSG donor site wound. The main question[s] it aims to answer are: - the effectiveness of different donor site dressings and their adverse outcomes - the satisfaction of patients with the donor site dressing will be observed. Participants will randomly allocated different types of dressings for split thickness skin graft donor site wound which include alginate hydrocolloid hydrofiber silicon film guaze

NCT ID: NCT05335720 Completed - Skin Graft Scar Clinical Trials

Efficacy and Safety Evaluation of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site)

Start date: July 19, 2019
Phase: N/A
Study type: Interventional

This study is a prospective study, randomized, using control, open-label, single-center to evaluate the efficacy and safety of EASYEF® in acute wound (split-thickness skin graft donor site). A total of 10 subjects are randomly allocated. Subjects who meet the final inclusion and exclusion criteria are randomized to the test cohorts in a ratio of 1:1:1.

NCT ID: NCT04176705 Completed - Burn Scar Clinical Trials

Fractional Ablative Laser Treatment for Skin Grafts

Start date: December 14, 2020
Phase: N/A
Study type: Interventional

Doctors and patients refer to all areas of skin changes from burn injury as burn scars. However, different areas of scars from burns can be treated differently. The burn scars that come from skin grafting surgery might be improved with laser treatment. The purpose of this study is to see if treating burn skin graft scars with a laser could make it better. Fractional Ablative Laser has been approved by the US Food and Drug Administration (FDA), but it has not been approved for use in the early stages of scar maturation and is considered investigational for this study.